In addition to treating obesity and Type 2 diabetes, GLP-1s have also shown promise with substance use disorders (SUD)
Exenatide use was associated with a 72% reduction (OR = 0.28, 95% CI: 0.13-0.59, p = 0.0008), and liraglutide with a 71% reduction (OR = 0.29, 95% CI: 0.19-0.46, p = 0.0001)
For example, VSL#3, a mix of eight different bacteria, has been shown to help prevent and treat obesity and type 2 diabetes [2]
Contact Casey Law Offices, S.C., where experienced Ozempic attorneys are ready to help
Ozempic and Semaglutide are brand names of the medication semaglutide, developed and produced by pharmaceutical company Novo Nordisk
Dipeptidyl peptidase IV inhibitors, a promising new therapeutic approach for the management of type 2 diabetes